Hengdi Pharmaceutical (301211.SZ) released its performance in the first half of the year, with a net profit attributable to the parent company of 18.5471 million yuan, a decrease of 72.92%.

Zhixin Finance APP News, Hengdi Pharmaceutical (301211.SZ) released its 2025 semi-annual report, with the company's operating income of 235 million yuan, a decrease of 2.93% year-on-year. Net profit attributable to the shareholders of the listed company was 18.5471 million yuan, a decrease of 72.92% year-on-year. Net profit attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 4.4162 million yuan, a decrease of 93.21% year-on-year. Basic earnings per share was 0.06 yuan. In addition, it is proposed to increase 4.5 shares for every 10 shares to all shareholders.